Trade in substandard and falsified medicines

Trade in substandard and falsified medicines

According to WHO, 10.5% of medicines in low- and middle-income countries are substandard or falsified (SF), which has a multidimensional impact on public health as well as severe economic and socioeconomic consequences. Constrained access, weak technical capacity and poor governance contribute to th...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Hagen, N, Hauk, C, Heide, L
Kolejni autorzy:	Brombacher, D
Format:	Book section
Język:	English
Wydane:	Nomos 2022

Podobne zapisy

Identification of substandard and falsified medicines: influence of different tolerance limits and use of authenticity inquiries
od: Hauk, C, i wsp.
Wydane: (2021)

Substandard and Falsified Medicines in Myanmar
od: Mirai Sakuda, i wsp.
Wydane: (2020-03-01)

The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance
od: Cavany, S, i wsp.
Wydane: (2023)

The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance
od: Sean Cavany, i wsp.
Wydane: (2023-10-01)

How to achieve international action on falsified and substandard medicines.
od: Attaran, A, i wsp.
Wydane: (2012)

The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists
od: Veronika J Wirtz, i wsp.
Wydane: (2019-07-01)

Combatting substandard and falsified medicines: a view from Rwanda.
od: Agnes Binagwaho, i wsp.
Wydane: (2013-01-01)

Substandard, falsified and unregistered medicines in Latin America, 2017-2018
od: Robin Rojas-Cortés
Wydane: (2020-10-01)

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance
od: Elizabeth Pisani, i wsp.
Wydane: (2021-08-01)

Falsified and substandard medicines trafficking: A wakeup call for the African continent
od: Yusuf Hassan Wada, i wsp.
Wydane: (2022-06-01)

Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications
od: Faris El-Dahiyat, i wsp.
Wydane: (2021-10-01)

Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
od: Albert Petersen, i wsp.
Wydane: (2017-01-01)

Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?
od: Paul N Newton, i wsp.
Wydane: (2022-08-01)

Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?
od: Zabala, GA, i wsp.
Wydane: (2022)

Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines
od: Tamara Akpobolokemi, i wsp.
Wydane: (2022-01-01)

The economic impact of substandard and falsified antimalarial medications in Nigeria.
od: Sarah M Beargie, i wsp.
Wydane: (2019-01-01)

The Future of Falsified and Substandard Medicine Detection: Digital Methods To Track and Authenticate Pharmaceutical Products
od: Naughton, B
Wydane: (2018)

A random survey of the prevalence of falsified and substandard antibiotics in the Lao PDR
od: Tabernero, P, i wsp.
Wydane: (2022)

A random survey of the prevalence of falsified and substandard antibiotics in the Lao PDR
od: Tabernero, P, i wsp.
Wydane: (2019)

Technologies for detecting falsified and substandard drugs in low and middle-income countries.
od: Stephanie Kovacs, i wsp.
Wydane: (2014-01-01)

Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab
od: Gesa Gnegel, i wsp.
Wydane: (2022-07-01)

The concept of substandard (falsified and poor quality) industrial products and its types
od: K. A. Utarov, i wsp.
Wydane: (2022-09-01)

The concept of substandard (falsified and poor quality) industrial products and its types
od: K. A. Utarov, i wsp.
Wydane: (2022-09-01)

Substandard and falsified medical products: bibliometric analysis and mapping of scientific research
od: Waleed M. Sweileh
Wydane: (2021-09-01)

Mobile apps for detecting falsified and substandard drugs: A systematic review.
od: Agustín Ciapponi, i wsp.
Wydane: (2021-01-01)

Exploring pharmacists' perspectives about substandard and falsified medical products through interviews
od: A. Persson, i wsp.
Wydane: (2024-03-01)

Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review
od: Biset Asrade Mekonnen, i wsp.
Wydane: (2024-12-01)

Quantitative screening of the pharmaceutical ingredient for the rapid identification of substandard and falsified medicines using reflectance infrared spectroscopy.
od: Graham Lawson, i wsp.
Wydane: (2018-01-01)

A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country
od: Daariimaa Khurelbat, i wsp.
Wydane: (2020-05-01)

Substandard and falsified antimicrobials in selected east African countries: A systematic review.
od: Addisu Afrassa Tegegne, i wsp.
Wydane: (2024-01-01)

Substandard and falsified antimicrobials in selected east African countries: A systematic review
od: Addisu Afrassa Tegegne, i wsp.
Wydane: (2024-01-01)

Screening for substandard and falsified medicines in Nigeria using visual inspection and GPHF-Minilab analysis: lessons learnt for future training of health workers and pharmacy personnel
od: Micha Lächele, i wsp.
Wydane: (2024-12-01)

A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality
od: McManus, D, i wsp.
Wydane: (2020)

A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality
od: Dominic McManus, i wsp.
Wydane: (2020-08-01)

Unveiling the Peril of Substandard and Falsified Medicines to Public Health and Safety in Africa: Need for All-Out War to End the Menace
od: Nafiu Aminu, i wsp.
Wydane: (2017-01-01)

Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study.
od: Colleen R Higgins, i wsp.
Wydane: (2023-01-01)

Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study
od: Colleen R. Higgins, i wsp.
Wydane: (2023-01-01)

Small-scale dissolution test screening tool to select potentially substandard and falsified (SF) medicines requiring full pharmacopoeial analysis
od: Mohammad Sofiqur Rahman, i wsp.
Wydane: (2021-06-01)

Cost savings of paper analytical devices (PADs) to detect substandard and falsified antibiotics: Kenya case study
od: Hui-Han Chen, i wsp.
Wydane: (2021-03-01)

Substandard, Spurious, Falsely-Labelled, Falsified and Counterfeit (SSFFC) Drugs: Time to Take a Bitter Pill
od: Geetha Mani, i wsp.
Wydane: (2016-10-01)